ADEL Inc.
- Biotech or pharma, therapeutic R&D
ADEL Inc. is a clinical-stage biotech company developing innovative antibody therapeutics, diagnostics, and platform technologies for Alzheimer's disease and beyond. Our pipeline includes:
- ADEL-Y01, a Tau-MTBR antibody for Alzheimer’s disease
- ADEL-Y04, an ApoE4-targeting antibody for Alzheimer’s and cardiometabolic diseases
- ADEL-Y03, a b2m antibody for Alzheimer’s, kidney, inflammatory, and oncology indications
- Diagnostic antibodies enabling early detection of Alzheimer’s disease
- BTS platform (Brain Targeting System) to enhance BBB penetration of biologics
- ADTAC platform (Autophagy-based Targeted Protein Degradation) for degrading previously undruggable targets
We are actively seeking global R&D collaborations and licensing opportunities.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}